L ANELLO MAGNETICO NELLA TERAPIA DEL REFLUSSO

Transcription

1 L ANELLO MAGNETICO NELLA TERAPIA DEL REFLUSSO GASTROESOFAGEO Greta Saino University of Milan Department of Biomedical Sciences for Health Division of General Surgery IRCCS Policlinico San Donato TOP TEN IN GASTROENTEROLOGIA TOP TEN IN GASTROENTEROLOGIA ISEO, MARZO 2015

2 The burden of gastroesophageal reflux disease in the world North America: 18-27% Europe: 9-25% South America: 23% Australia: 11% East Asia: 3-8% PJ P.J. Kahrilas Symptomatic reflux disease: the present, the past and the future Postgrad Med J,2015 NJ Shaheen N.J. Shaheen Burden of Gastrointestinal Disease in the United States Gastroenterology, 2012

3 THE GAP BETWEEN MEDICAL AND SURGICAL THERAPY MEDICAL THERAPY SURGICAL THERAPY (FUNDO) > 90% 60% < 10% The rise and fall of antireflux surgery in the United States JF Finks, 2006, Surgical Endoscopy

4 EVOLUTION OF ANTIREFLUX SURGERY: PIONEERS The esophagogastric p g g angle should be reconstituted by fixing the cardia below the diaphragm and so allowing the fundus of stomach to ballon up under the dome Philip Allison, S rg Gynecol Surg G necol Obstet, Obstet 1951 Norman Barrett Br J Surg, 1954 Ronald Belsey J Thorac Cardiovasc Surg, 1961

5 EVOLUTION OF ANTIREFLUX SURGERY: THE DOGMA SINCE A HALF OF CENTURY Andrè Toupet Mem Acad Chir 1963 Rudolf Nissen Schweiz Med Wochenschr, 1956

6 ANTIREFLUX SURGERY ( ) 2014) n = ,2 % 4,1 % 21,4 % 56,3 % NISSEN (n=417) TOUPET (n=182) LINX (n=143) OTHER (n=40) IRCCS Policlinico San Donato

7

8 DISTRIBUTION OF ANTIREFLUX PROCEDURES ( ) 2013) No. pts Nissen Toupet Linx IRCCS Policlinico San Donato

9 ISSUES WITH NISSEN FUNDOPLICATION Technically complex Alters gastricanatomy ti anatomy Operator-dependent Side effects Variable success rate Not reversible reserved for severe GERD Vakil et al, Am JMed 2003

10 WHICH IS THE IDEAL GERD TREATMENT? Restore LES barrier function Preserve normal physiology (ability to swallow belch and vomit) Minimally invasive Standardize efficacy and outcomes Reversible if necessary Outpatient procedure

11

12 FEASIBILITY TRIAL: FIRST IMPLANT Policlinico san Donato, March, 17 TH, 2007

13 MAGNETIC SPHINCTER AUGMENTATION: CLINICAL EXPERIENCE Feasibility trial 30 Policlinico San Donato, Milano. 7 Northwestern t Hospital, Minneapolis, Minnesota 3 Chapman Medical Center, Orange, California (Bonavina L et al, J Gastrointest Surg 2008; Bonavina L et al, Ann Surg 2010; Lipham J et al,surg Endosc 2012) Pivotal trial (Ganz R et al, New Engl J Med 2013) Italian registry (Bonavina L et al, J Am Coll Surg, 2013)

14

15 All devices implanted laparoscopically No intra-operative complications Median operative time 40 minutes (range19-104) 43/44 patients discharged within 48 hours post-implant No serious adverse events during hospitalization Patients resumed normal diet post-implant Dysphagia most common adverse event, motly miold and resolved by 3 months No device erosins or migrations

16

17 30 N=44 PI (Mean n) RQL Sco ore Off P GERD H N=37 N=33 N=27 N=23 p<0.001 p=0.003 p<0.001 p< BL Off PPI Year 1 Year 2 Year 3 Year >=4

18

19 Clinical Outcomes by Implant Group GERD-HRQL Score (Median) Group 1 (Pts 1 25) 15 Group 2 (Pts 26 50) 10 Group 3 (Pts 51 75) 5 Group 4 (Pts ) 0 Baseline Last Follow up 100 %of Patients ate tswith PPI Use Baseline Last Follow up Group 1 (Pts 1 25) Group 2 (Pts 26 50) Group 3 (Pts 51 75) Group 4 (Pts )

20 Daily PPI Use N=44 N=35 N=32 N=25 N=39 Baseline Year 1 Year 2 Year 3 Year >=4 Patients Reporting Daily PP PI Use (% %)

21 No. pts Sex Implant date Crural repair Size Time to explant (mos.) Reason Associated procedure POZZI R 002 M 12/2009 yes DARDANO R 006 F 01/2010 no Odynophagia &chest pain Heartburn &regurgitation (previous MR) Dor Toupet (+crura repair) PERFETTI R 081 M 11/2011 yes Dysphagia Lortat-Jacob DI PIETRO R 102 M 04/2012 no Heartburn Toupet (+crura repair) DI GREGORI O R 101 M 04/2012 no Dysphagia FERRARI R 076 M 09/2011 yes Heartburn &regurgitation Toupet (+crura repair) Nissen (+crura repair) BAIETTA R 093 M 02/2012 yes Dysphagia&vomiting yp g Dor CAGNI R 110 F 05/2012 yes Regurgitation Toupet ROSSI R 125 M 03/2013 yes Dysphagia Dor BARBERO R118 M 12/2012 yes Heartburn & epigastric pain Toupet

22

23 MAGNETIC RESONANCE AND LINX 8 (8,3%) patients underwent postop. MR 5 pts (1,5 Tesla); l) 2pts (0,5 Tesla);1 l) pt (0,2 Tesla) l) 2/5 1,5 T experienced level 8 discomfort

24 PREGNANCY TESTED DEVICE Pre-pregnancy p g y R 079 Post-pregnancy p g y R 079

25 CONCLUSIONS LINX can improve reflux symptoms and allow discontinuation of PPI with minimal side effects in patients with early-stage GERD. LINX can reduce the variability in outcomes observed with traditional antireflux surgery. A more pragmatic rather than dogmatic surgical approach in GERD is probably worthwhile. pp p y

26

27

28 Whether justified or not, it is clear that fewer patients with GERD are undergoing surgical intervention. i Whichh therapeutic approachmedical, surgical or endoscopic- is best suited for which patients is an important question that remains unanswered. The rise and fall of antireflux surgery in the The rise and fall of antireflux surgery in the United States J.F. Finks, Surgical Endoscopy, 2006